Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer
Wolfgang Janni, MD, PhD
Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.
According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.
The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.